GSK vs PFE

For growth investors, GSK plc (GSK) is the stronger pick with 4.

1% revenue growth year-over-year, versus -1. 6% for Pfizer Inc. (PFE). GSK plc (GSK) offers the better valuation at 6. 7x trailing P/E (10. 4x forward), making it the more compelling value choice. Analysts rate GSK plc (GSK) a "Hold" — based on 29 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, GSK plc (GSK) is the cheapest at 6.

7x versus Pfizer Inc. at 18. 9x. On forward P/E, Pfizer Inc. is actually cheaper at 8. 7x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, GSK plc (GSK) delivered a total return of +52.

6%, compared to -14. 8% for Pfizer Inc. (PFE). Over 10 years, the gap is even starker: GSK returned +62. 8% versus PFE's +28. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), GSK plc (GSK) is the lower-risk stock at 0.

44β versus Pfizer Inc. 's 0. 49β — meaning PFE is approximately 12% more volatile than GSK relative to the S&P 500. On balance sheet safety, Pfizer Inc. (PFE) carries a lower debt/equity ratio of 78% versus 111% for GSK plc — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), GSK plc (GSK) is pulling ahead at 4.

1% versus -1. 6% for Pfizer Inc. (PFE). On earnings-per-share growth, the picture is similar: GSK plc grew EPS 348. 4% year-over-year, compared to -3. 5% for Pfizer Inc.. Over a 3-year CAGR, GSK leads at 3. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

GSK plc (GSK) is the more profitable company, earning 17.

5% net margin versus 12. 4% for Pfizer Inc. — meaning it keeps 17. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: GSK leads at 25. 5% versus 24. 7% for PFE. At the gross margin level — before operating expenses — GSK leads at 72. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Pfizer Inc.

(PFE) trades at 8. 7x forward P/E versus 10. 4x for GSK plc — 1. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PFE: 6. 7% to $27. 40.

All stocks in this comparison pay dividends.

Pfizer Inc. (PFE) offers the highest yield at 6. 7%, versus 6. 6% for GSK plc (GSK).

For long-horizon retirement investors, GSK plc (GSK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

44), 6. 6% yield). Both have compounded well over 10 years (GSK: +62. 8%, PFE: +28. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: GSK is a mid-cap deep-value stock; PFE is a mid-cap income-oriented stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.